Business
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
SAN DIEGO, August 13, 2025--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the appointment of Sam Whiting, M.D., Ph.D., as Chief Medical Officer. Dr. Whiting is an accomplished medical oncologist who brings to Vividion more than two decades of experience spanning patient care, early drug discovery, and late-stage global clinical development. Vividion utilizes innovative disc
About this update from Tempest Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f52d8cdfc3f5cb6de5a844a6c8df2ed9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/evuNHOal.Kz8ys0AuRSQUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f52d8cdfc3f5cb6de5a844a6c8df2ed9","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.SmP6781PvqikEOwvIu5vQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/f52d8cdfc3f5cb6de5a844a6c8df2ed9","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Whiting brings extensive experience in medical oncology spanning patient care, early drug discovery, and late-stage global development activities","length":149,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"His leadership will deepen the company’s clinical expertise to support progress of its portfolio of innovative investigational therapies for cancers and immune disorders","length":169,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Dr. Whiting joins from Tempest Therapeutics where he orchestrated successful clinical trials of multiple investigative small molecules for cancer","length":145,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":463,"olType":false},{"type":"text","content":"SAN DIEGO, August 13, 2025--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the appointment of Sam Whiting, M.D., Ph.D., as Chief Medical Officer. Dr. Whiting is an accomplished medical oncologist who brings to Vividion more than two decades of experience spanning patient care, early drug discovery, and late-stage global clinical development. Vividion utilizes innovative discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders.","length":697,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Sam as our Chief Medical Officer at a pivotal time ...